Thu, March 3, 2022
Wed, March 2, 2022
Tue, March 1, 2022
Mon, February 28, 2022
Sun, February 27, 2022
Fri, February 25, 2022

David Lebowitz Initiated (ASND) at Strong Buy and Held Target at $187 on, Mar 1st, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. -buy-and-held-target-at-187-on-mar-1st-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

David Lebowitz of Citigroup, Initiated "Ascendis Pharma A/S" (ASND) at Strong Buy and Held Target at $187 on, Mar 1st, 2022.

David has made no other calls on ASND in the last 4 months.



There are 5 other peers that have a rating on ASND. Out of the 5 peers that are also analyzing ASND, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Yaron Werber of "Cowen & Co." Initiated at Hold and Held Target at $136 on, Thursday, January 6th, 2022


These are the ratings of the 4 analyists that currently disagree with David


  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $170 on, Monday, February 14th, 2022
  • Derek Archila of "Wells Fargo" Initiated at Buy and Held Target at $176 on, Wednesday, December 8th, 2021
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $190 on, Monday, November 15th, 2021
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $179 on, Thursday, November 11th, 2021

Publication Contributing Sources